Indonesia has succeeded in making a domestically made Covid-19 vaccine called Indovac. The launch was carried out directly by President Joko Widodo (Jokowi), Thursday (13/10). This inauguration marks the beginning of this vaccine being used in the national vaccination program.
With the launch of this domestically made vaccine, the President hopes that Indonesia can be independent in vaccine matters.
“By saying bismillahirrahmanirrahim, this morning I launched the Indovac vaccine produced by PT Bio Farma, Bandung,” Jokowi said as broadcast on the Presidential Secretariat’s YouTube.
“And starting today, we can produce our own Covid-19 vaccine with a capacity this year of approximately 20 million. Earlier, the President Director (of PT Bio Farma) said, next year it could be 40 million, and if the market still needs it, it can reach 120 million doses of vaccine,” he explained.
The Head of State then explained that the launch of the Indovac vaccine was the hard work of young Indonesian human resources who were able to work on a new vaccine from upstream to downstream.
“It has taken Indovac from the beginning until now 1.5 years. Also silent, never made a sound, suddenly became Indovac,” said Jokowi.
Therefore, Jokowi asked SOE Minister Erick Thohir and Health Minister Budi Gunadi Sadikin to continue to encourage vaccine production at PT Bio Farma. So that later it will generate greater revenue for Indonesia.
“And we have complete independence in the matter of vaccines,” said Jokowi.
As is known, Indovac is the first Covid-19 vaccine that is a domestic product that has received an emergency use authorization (EUA) or an emergency use permit. The official Indovac vaccine emergency use permit was issued on September 24, 2022.
“We have received emergency use authorization, the first is the Indovac Vaccine. This is a vaccine that is domestic development,” said Head of BPOM Penny K Lukito on September 30, 2022.
Penny said Indovac is produced locally in the country from upstream to downstream processes.
“This is a vaccine that is a domestic development. Although at the beginning of the course it collaborated with research institutions from the Baylor College of Medicine in the US, then it was developed in stages starting from pre-clinical, phase I, II, and III clinical trials in Indonesia, namely in Indonesia. Bio Farma,” said Penny.